title: Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT.
abstract: BACKGROUND
  We administered an angiotensin-converting enzyme inhibitor (captopril) to mice implanted with a human lung adenocarcinoma epithelial cell line (A549 cells) and investigated the tumor growth-inhibitory effect of captopril from the viewpoint of glucose metabolism using (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/CT.
  
  
  METHODS
  Subcutaneous implantation of A549 cells (1.9×10(6) cells) was carried out in the lower right flank of mice. Fifteen days after the transplantation of A549 cells, mice (six in each group) were treated with captopril (3.0 mg/mouse) or saline (1000 μl/mouse) for 5 days. We performed (18)F-FDG-PET/CT imaging of the mice before and after the treatment and evaluated the degree of (18)F-FDG accumulation in tumors. In both groups (the captopril-administrated and control groups), values for the metabolic tumor volume (MTV), maximum standardized uptake value, total lesion glycolysis, and tumor volume after treatment had a tendency to increase. However, tumor growth was suppressed in the captopril-administrated group compared with the control group.
  
  
  RESULTS
  In terms of the growth rate, the MTV and tumor volume were significantly different (P<0.05). It was found that captopril exerted a potential tumor growth-inhibitory effect; this was because the captopril-administrated group showed low values of MTV, maximum standardized uptake value, total lesion glycolysis, and tumor volume in comparison with the control group.
authors.affiliation: aDepartment of Radiological Technology, Faculty of Health Science, Suzuka University of Medical Science, Mie bDepartment of Medical Imaging/Nuclear Medicine cDepartment of Oncological Medical Services, Institute of Biomedical Sciences dProgram in Medical Imaging Biosciences, Division of Health Sciences, Tokushima University Graduate School, Tokushima, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Nakaya
authors.forename: Hideki
authors.initials: H
authors.lastname: Otsuka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kondo
authors.forename: Tamaki
authors.initials: T
authors.lastname: Otani
authors.forename: Motoi
authors.initials: M
authors.lastname: Nagata
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002216:Captopril / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed; D023041:Xenograft Model Antitumor Assays
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019788:Fluorodeoxyglucose F18; D002216:Captopril; D005947:Glucose